Namodenoson Treatment of Advanced Pancreatic Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorCan-Fite BioPharma
About this trial
This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients.
Eligibility criteria
Qualifiers
Males and females at least 18 years of age.
Histologically or cytologically confirmed pancreatic adenocarcinoma, or clinically diagnosed based upon scan results and a serum Cancer Antigen 19-9 value >1000 U/mL on at least 1 occasion.
Pancreatic adenocarcinoma is advanced (i.e., treatment-refractory or metastatic) and no standard therapies are expected to be curative.
Pancreatic adenocarcinoma has progressed on at least 1 prior systemic treatment regimen, or the patient refuses standard treatment.
Disqualifiers
Receipt of systemic cancer therapy within 14 days prior to the Baseline Visit or concurrently during the trial.
Persistent toxicity ≥Grade 2 from previous cancer therapy, with the exceptions of alopecia and Grade 3 peripheral neuropathy.
Major surgery or radiation therapy within 14 days prior to the Baseline Visit.
Use of any investigational agent within the shorter of 4 weeks or 5 half-lives prior to the Baseline Visit.
Trial design
Treatments tested in this trial
- Namodenoson 25mg
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov